Brain, Vol. 125, No. 10, 2191-2201,
October 2002
© 2002 Oxford University Press
Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys
1 Department of Anatomy and Neurobiology and 2 Morris K. Udall Parkinson’s Disease Research Center of Excellence, University of Kentucky Medical Center, Lexington, KY, 3 Medtronic Inc., Medtronic Neurological Division, Minneapolis, MN and 4 AMGEN Inc., Thousand Oaks, CA, USA
Correspondence to: Dr Richard Grondin, Department of Anatomy and Neurobiology, University of Kentucky Medical Center, Room 305, Davis Mills Building, 800 Rose Street, Lexington, KY 40536-0098, USAE-mail: rcgron0{at}pop.uky.edu
The powerful trophic effects that glial cell line-derived neurotrophic factor (GDNF) exerts on midbrain dopamine neurones suggest its use in treating Parkinson’s disease. However, some important questions remain about the possible therapeutic applications of GDNF. Here we demonstrate that the chronic infusion of 5 or 15 µg/day GDNF into the lateral ventricle or the striatum, using programmable pumps, promotes restoration of the nigrostriatal dopaminergic system and significantly improves motor functions in rhesus monkeys with neural deficits modelling the terminal stages of Parkinson’s disease. The functional improvements were associated with pronounced upregulation and regeneration of nigral dopamine neurones and their processes innervating the striatum. When compared with vehicle recipients, these functional improvements were associated with (i) >30% bilateral increase in nigral dopamine neurone cell size; (ii) >20% bilateral increase in the number of nigral cells expressing the dopamine marker tyrosine hydroxylase; (iii) >70 and >50% bilateral increase in dopamine metabolite levels in the striatum and the pallidum, respectively; (iv) 233 and 155% increase in dopamine levels in the periventricular striatal region and the globus pallidus, respectively, on the lesioned side; and (v) a five-fold increase in tyrosine hydroxylase-positive fibre density in the periventricular striatal region on the lesioned side. In addition, chronic GDNF treatment did not induce the side-effects generally associated with chronic administration of levodopa, the most widely used treatment for Parkinson’s disease. Thus, the results suggest that the prolonged and controlled delivery of GDNF into the brain could be used to intervene in long-term neurodegenerative disease processes like Parkinson’s disease. Additional studies are required to determine the potential differences between chronic, intraventricular and intraputamenal (or intranigral) delivery of GDNF to maximize the efficacy of infusion treatments.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  N. P. Visanji, A. Orsi, T. H. Johnston, P. A. Howson, K. Dixon, N. Callizot, J. M. Brotchie, and D. D. Rees PYM50028, a novel, orally active, nonpeptide neurotrophic factor inducer, prevents and reverses neuronal damage induced by MPP+ in mesencephalic neurons and by MPTP in a mouse model of Parkinson's disease FASEB J, July 1, 2008; 22(7): 2488 - 2497. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. McCann and B. N. Ames Is there convincing biological or behavioral evidence linking vitamin D deficiency to brain dysfunction? FASEB J, April 1, 2008; 22(4): 982 - 1001. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. N. Hovland Jr., R. B. Boyd, M. T. Butt, J. A. Engelhardt, M. S. Moxness, M. H. Ma, M. G. Emery, N. B. Ernst, R. P. Reed, J. R. Zeller, et al. Reprint: Six-Month Continuous Intraputamenal Infusion Toxicity Study of Recombinant Methionyl Human Glial Cell Line-Derived Neurotrophic Factor (r-metHuGDNF) in Rhesus Monkeys Toxicol Pathol, December 1, 2007; 35(7): 1013 - 1029. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. N. Hovland Jr., R. B. Boyd, M. T. Butt, J. A. Engelhardt, M. S. Moxness, M. H. Ma, M. G. Emery, N. B. Ernst, R. P. Reed, J. R. Zeller, et al. Six-Month Continuous Intraputamenal Infusion Toxicity Study of Recombinant Methionyl Human Glial Cell Line-Derived Neurotrophic Factor (r-metHuGDNF) in Rhesus Monkeys Toxicol Pathol, August 1, 2007; 35(5): 676 - 692. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Minguez-Castellanos, F. Escamilla-Sevilla, G. R Hotton, J. J Toledo-Aral, A. Ortega-Moreno, S. Mendez-Ferrer, J. M Martin-Linares, M. J Katati, P. Mir, J. Villadiego, et al. Carotid body autotransplantation in Parkinson disease: a clinical and positron emission tomography study J. Neurol. Neurosurg. Psychiatry, August 1, 2007; 78(8): 825 - 831. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A H V Schapira Present and future drug treatment for Parkinson's disease J. Neurol. Neurosurg. Psychiatry, November 1, 2005; 76(11): 1472 - 1478. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Villadiego, S. Mendez-Ferrer, T. Valdes-Sanchez, I. Silos-Santiago, I. Farinas, J. Lopez-Barneo, and J. J. Toledo-Aral Selective Glial Cell Line-Derived Neurotrophic Factor Production in Adult Dopaminergic Carotid Body Cells In Situ and after Intrastriatal Transplantation J. Neurosci., April 20, 2005; 25(16): 4091 - 4098. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Maswood, J. Young, E. Tilmont, Z. Zhang, D. M. Gash, G. A. Gerhardt, R. Grondin, G. S. Roth, J. Mattison, M. A. Lane, et al. Caloric restriction increases neurotrophic factor levels and attenuates neurochemical and behavioral deficits in a primate model of Parkinson's disease PNAS, December 28, 2004; 101(52): 18171 - 18176. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. S. Roth, J. A. Mattison, M. A. Ottinger, M. E. Chachich, M. A. Lane, and D. K. Ingram Aging in Rhesus Monkeys: Relevance to Human Health Interventions Science, September 3, 2004; 305(5689): 1423 - 1426. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Grondin, W. A. Cass, Z. Zhang, J. A. Stanford, D. M. Gash, and G. A. Gerhardt Glial Cell Line-Derived Neurotrophic Factor Increases Stimulus-Evoked Dopamine Release and Motor Speed in Aged Rhesus Monkeys J. Neurosci., March 1, 2003; 23(5): 1974 - 1980. [Abstract] [Full Text] [PDF]
|
|